This preprint is under consideration at Diagnostic Pathology. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Significance of Detecting the Levels of miR-29a, Survivin and Igras in Patients With Lung Cancer and Tuberculosis
lijuan sun
Department of respiratory and critical care The Fifth Affiliated Hospital of Zhengzhou University, No. 3 of Kangfu Street, Erqi District, Zhengzhou 450000,China
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background:When lung cancer is combined with tuberculosis at the same time, it is easy to be misdiagnosed and missed. The purpose of this article is to provide reference for patients with lung cancer complicated by active pulmonary tuberculosis.
Methods:The concentration of survivin in diseased tissue and miR-29a and IGRAs in serum in 25 patients with non-small-cell lung carcinoma (NSCLC) complicated by active pulmonary tuberculosis (APT) and 32 patients with NSCLC and 30 patients with APT were measured.
Results:The expressions of miR-29a in serum of the APT group were higher than those of the NSCLC complicated by APT group and the NSCLC group (p<0.05). The expressions of survivin in diseased tissue of the NSCLC complicated by APT group and the NSCLC group were higher than those of the APT group (p<0.05).The expression level of IGRAs in serum of the NSCLC complicated by APT group and the APT group was higher than those of the NSCLC group (p<0.05), the expression level of IGRAs in serum of the NSCLC complicated by APT group was higher than the APT group.
Conclusion:We should be on guard against patients with APT complicated by lung cancer, when miR-29a was low expression in serum and survivin was high expression in diseased tissue of the patient who was pathologically diagnosed with APT. We should be on the alert for patients with lung cancer complicated by APT, when miR-29a was high expression in serum and survivin was low expression in diseased tissue and IGRAs was high level in serum of the patient with lung cancer.
Keywords
NSCLC, active pulmonary tuberculosis, miR-29a, survivin, IGRAs
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 11 Jan, 2021
No community comments so far
Reviewer #3 agreed
On 17 Jan, 2021
Review #1 received
Received 16 Jan, 2021
Reviewer #2 agreed
On 15 Jan, 2021
Reviewer #1 agreed
On 14 Jan, 2021
Reviewers invited
Invitations sent on 04 Jan, 2021
First submitted
On 03 Jan, 2021
Editor assigned
On 03 Jan, 2021
Submission checks complete
On 03 Jan, 2021
Editor invited
On 03 Jan, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Pathology
Learn more about our company.
This preprint is under consideration at Diagnostic Pathology. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Significance of Detecting the Levels of miR-29a, Survivin and Igras in Patients With Lung Cancer and Tuberculosis
lijuan sun
Department of respiratory and critical care The Fifth Affiliated Hospital of Zhengzhou University, No. 3 of Kangfu Street, Erqi District, Zhengzhou 450000,China
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 11 Jan, 2021
No community comments so far
Reviewer #3 agreed
On 17 Jan, 2021
Review #1 received
Received 16 Jan, 2021
Reviewer #2 agreed
On 15 Jan, 2021
Reviewer #1 agreed
On 14 Jan, 2021
Reviewers invited
Invitations sent on 04 Jan, 2021
First submitted
On 03 Jan, 2021
Editor assigned
On 03 Jan, 2021
Submission checks complete
On 03 Jan, 2021
Editor invited
On 03 Jan, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Pathology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background:When lung cancer is combined with tuberculosis at the same time, it is easy to be misdiagnosed and missed. The purpose of this article is to provide reference for patients with lung cancer complicated by active pulmonary tuberculosis.
Methods:The concentration of survivin in diseased tissue and miR-29a and IGRAs in serum in 25 patients with non-small-cell lung carcinoma (NSCLC) complicated by active pulmonary tuberculosis (APT) and 32 patients with NSCLC and 30 patients with APT were measured.
Results:The expressions of miR-29a in serum of the APT group were higher than those of the NSCLC complicated by APT group and the NSCLC group (p<0.05). The expressions of survivin in diseased tissue of the NSCLC complicated by APT group and the NSCLC group were higher than those of the APT group (p<0.05).The expression level of IGRAs in serum of the NSCLC complicated by APT group and the APT group was higher than those of the NSCLC group (p<0.05), the expression level of IGRAs in serum of the NSCLC complicated by APT group was higher than the APT group.
Conclusion:We should be on guard against patients with APT complicated by lung cancer, when miR-29a was low expression in serum and survivin was high expression in diseased tissue of the patient who was pathologically diagnosed with APT. We should be on the alert for patients with lung cancer complicated by APT, when miR-29a was high expression in serum and survivin was low expression in diseased tissue and IGRAs was high level in serum of the patient with lung cancer.